Sildisoft Tablets (which contain Sildenafil Citrate) are typically studied by: 1. Pharmaceutical Companies: When a new drug like Sildisoft is developed, the manufacturer (the pharmaceutical company) conducts clinical trials to evaluate its safety, efficacy, and side effects over both the short term and long term. These trials are conducted in phases (I, II, III, and sometimes IV) to gather data about how the drug works in different populations and over various periods. After approval, phase IV trials (post-marketing surveillance) are conducted to monitor the long-term safety and any rare or delayed side effects in the general population. 2. Regulatory Authorities: Regulatory bodies like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and others worldwide review clinical trial data before granting approval for a medication like Sildisoft. They also require post-market studies (long-term safety studies) to track how the medication performs in the broader population over time. These authorities may mandate safety monitoring after the drug is approved and sold, requiring ongoing reporting from healthcare providers and patients about adverse effects. 3. Academic Researchers and Medical Institutions: After a drug is approved, university-based researchers and medical institutions may conduct long-term observational studies or meta-analyses to assess the long-term effects and safety of drugs like Sildisoft in larger, diverse populations. They often publish their findings in medical journals and present the results at medical conferences. These studies can be especially valuable for understanding long-term risks, such as cardiovascular effects, vision problems, or effects on ***** health over prolonged use.